Even though there is no evidence that heparin may precipitate VITT, the similar pathogenesis of heparin-induced thrombocytopenia (e.g., appearance of anti-PF4 antibodies) makes it seem prudent to replace heparin-like with non- heparin-like anticoagulants if administration of a viral vector non-replicating vaccine is planned [34]. The gene discussed is PF4; the disease is Thrombocytopenia.